JO2976B1 - Axentomodulin polypeptide - Google Patents

Axentomodulin polypeptide

Info

Publication number
JO2976B1
JO2976B1 JO2010438A JOP20100438A JO2976B1 JO 2976 B1 JO2976 B1 JO 2976B1 JO 2010438 A JO2010438 A JO 2010438A JO P20100438 A JOP20100438 A JO P20100438A JO 2976 B1 JO2976 B1 JO 2976B1
Authority
JO
Jordan
Prior art keywords
peptide analogue
oxyntomodulin peptide
oxyntomodulin
analogue
axentomodulin
Prior art date
Application number
JO2010438A
Other languages
Arabic (ar)
English (en)
Inventor
السينا-فيرنانديز 1-جورجيه
ديفيد كوهن 2-واين
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43587001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO2976(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2976B1 publication Critical patent/JO2976B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JO2010438A 2009-12-22 2010-12-09 Axentomodulin polypeptide JO2976B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28888809P 2009-12-22 2009-12-22
US35257610P 2010-06-08 2010-06-08

Publications (1)

Publication Number Publication Date
JO2976B1 true JO2976B1 (en) 2016-03-15

Family

ID=43587001

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2010438A JO2976B1 (en) 2009-12-22 2010-12-09 Axentomodulin polypeptide

Country Status (34)

Country Link
US (1) US8367607B2 (enExample)
EP (1) EP2515928B1 (enExample)
JP (1) JP5717759B2 (enExample)
KR (1) KR101399671B1 (enExample)
CN (1) CN102740873B (enExample)
AR (1) AR079345A1 (enExample)
AU (1) AU2010341651B2 (enExample)
BR (1) BR112012017348B1 (enExample)
CA (1) CA2784671C (enExample)
CL (1) CL2012001686A1 (enExample)
CO (1) CO6551738A2 (enExample)
CR (1) CR20120338A (enExample)
DK (1) DK2515928T3 (enExample)
DO (1) DOP2012000176A (enExample)
EA (1) EA022820B1 (enExample)
ES (1) ES2486675T3 (enExample)
HN (1) HN2012001321A (enExample)
HR (1) HRP20140616T1 (enExample)
IL (1) IL220161B (enExample)
JO (1) JO2976B1 (enExample)
MA (1) MA33825B1 (enExample)
MX (1) MX2012007438A (enExample)
MY (1) MY160773A (enExample)
NZ (1) NZ600731A (enExample)
PE (1) PE20121393A1 (enExample)
PH (1) PH12012501263B1 (enExample)
PL (1) PL2515928T3 (enExample)
PT (1) PT2515928E (enExample)
RS (1) RS53505B1 (enExample)
SG (1) SG181430A1 (enExample)
SI (1) SI2515928T1 (enExample)
TN (1) TN2012000302A1 (enExample)
TW (1) TWI423812B (enExample)
WO (1) WO2011087672A1 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
SI2718318T1 (sl) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina in le-te obsegajoča farmacevtska sestava za zdravljenje debelosti
ES2710356T3 (es) 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン/glp−1レセプタコ−アゴニスト
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
JP6290193B2 (ja) 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化oxm変異体
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI652071B (zh) 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
CA2891393A1 (en) 2012-11-20 2014-05-30 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2943359T3 (es) 2014-12-10 2023-06-12 Opko Biologics Ltd Métodos de producción de polipéptidos de hormona de crecimiento modificados con CTP de acción prolongada
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI700291B (zh) 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2017212494A1 (en) 2016-06-09 2017-12-14 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CN108299553B (zh) * 2017-01-13 2021-07-16 博瑞生物医药(苏州)股份有限公司 胃泌酸调节素修饰物
AU2019308089B2 (en) 2018-07-19 2025-04-10 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2204645A1 (en) * 1994-11-07 1996-05-17 Keiichi Yano Novel oxyntomodulin
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2006520818A (ja) 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合glp−1化合物
ATE482724T1 (de) 2005-05-13 2010-10-15 Lilly Co Eli Pegylierte glp-1-verbindungen
EP1891105B1 (en) * 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
AU2007221366B2 (en) * 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad

Also Published As

Publication number Publication date
AU2010341651B2 (en) 2014-01-16
NZ600731A (en) 2014-06-27
JP2013515057A (ja) 2013-05-02
TW201143793A (en) 2011-12-16
BR112012017348A2 (pt) 2017-01-10
CR20120338A (es) 2012-07-23
EA201290549A1 (ru) 2013-01-30
TWI423812B (zh) 2014-01-21
AU2010341651A1 (en) 2012-06-07
HK1170941A1 (en) 2013-03-15
US8367607B2 (en) 2013-02-05
DOP2012000176A (es) 2012-08-31
US20110152182A1 (en) 2011-06-23
WO2011087672A1 (en) 2011-07-21
PT2515928E (pt) 2014-09-03
PH12012501263A1 (en) 2013-02-04
IL220161A0 (en) 2012-07-31
CN102740873B (zh) 2014-11-05
CO6551738A2 (es) 2012-10-31
AR079345A1 (es) 2012-01-18
MY160773A (en) 2017-03-15
CN102740873A (zh) 2012-10-17
SI2515928T1 (sl) 2014-08-29
HN2012001321A (es) 2015-08-31
MX2012007438A (es) 2012-07-17
HRP20140616T1 (hr) 2014-08-15
CA2784671A1 (en) 2011-07-21
JP5717759B2 (ja) 2015-05-13
BR112012017348B1 (pt) 2019-11-05
RS53505B1 (sr) 2015-02-27
EA022820B1 (ru) 2016-03-31
KR101399671B1 (ko) 2014-05-27
CA2784671C (en) 2015-06-16
PE20121393A1 (es) 2012-10-26
IL220161B (en) 2018-12-31
ES2486675T3 (es) 2014-08-19
EP2515928B1 (en) 2014-06-18
DK2515928T3 (da) 2014-08-25
KR20120096022A (ko) 2012-08-29
EP2515928A1 (en) 2012-10-31
TN2012000302A1 (en) 2013-12-12
PH12012501263B1 (en) 2018-08-31
MA33825B1 (fr) 2012-12-03
PL2515928T3 (pl) 2014-11-28
SG181430A1 (en) 2012-07-30
CL2012001686A1 (es) 2012-11-23

Similar Documents

Publication Publication Date Title
JO2976B1 (en) Axentomodulin polypeptide
TN2012000303A1 (en) Oxyntomodulin peptide analogue
EA201000735A1 (ru) Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
IL210364A (en) Beta-amyloid peptide cyclic peptide analogue and its use in the treatment and diagnosis of neurodegenerative diseases or conditions
EP3570864A4 (en) PEPTIDES OF INTERLEUKIN-23 RECEPTOR INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
CY1123304T1 (el) Αναστολη πεπτιδιων που προερχονται απο μεταγραφημα 1 τυπου trem (tlt-1) και χρησεις αυτωn
IL204743A0 (en) Inhibition of macrophage - stimulating protein receptor (ron) and methods of treatment thereof
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
EP2240134C0 (en) METHODS AND INSTRUMENTS FOR TREATING OBESITY AND GASTROESOPHAGEAL REFLUX DISEASE
ZA200900379B (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
HRP20182195T1 (hr) Sekvence aminokiselina usmjerene protiv virusnih proteina ovojnice i polipeptidi koji sadrže iste za liječenje virusnih bolesti
IL210810B (en) Peptides to treat pain and/or inflammation
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
EP2024294A4 (en) PROCESSING OF PIEZOELECTRIC MATERIAL
EP2488205A4 (en) HUMAN RECOMBINANT CC10 PROTEIN FOR TREATMENT OF INFLUENZA
EA201190274A1 (ru) Конструкции casb7439
DK1959988T3 (da) Anvendelse af bovint lactoferrin til behandling af destruktiv inflammation af slimhinder
DK2118136T3 (da) Konsensuspeptid
DK2547694T5 (da) Hidtil ukendt signalpeptid og anvendelse deraf til fremstilling af rekombinante proteiner
MA32474B1 (fr) Nouveaux derives de (piperazinyl ponte) -1-alcanone et leur utilisation comme inhibiteurs de p75
EP2411406A4 (en) ISOFORMES NELL-1-PEPTIDE
UA106465C2 (en) Oxyntomodulin peptide analogue
PH12012501264A1 (en) Oxyntomodulin peptide analogue